Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab- guidance (TA629)

Obinutuzumab with bendamustine followed by obinutuzumab maintenance is recommended, as an option for treating follicular lymphoma that did not respond or progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen.

National Institute for Health and Care Excellence